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Abstract
LAIR-1 (Leukocyte Associated Ig-like Receptor -1) is a collagen receptor that functions as an inhibitory receptor on immune
cells. It has a soluble family member, LAIR-2, that also binds collagen and can interfere with LAIR-1/collagen interactions.
Collagen is a main initiator for platelet adhesion and aggregation. Here, we explored the potential of soluble LAIR proteins to
inhibit thrombus formation in vitro. LAIR-2/Fc but not LAIR-1/Fc inhibited collagen-induced platelet aggregation. In addition,
LAIR-2/Fc also interfered with platelet adhesion to collagen at low shear rate (300 s
21;I C 50=18mg/ml) and high shear rate
(1500 s
21;I C 50=30mg/ml). Additional experiments revealed that LAIR-2/Fc leaves interactions between collagen and a2b1
unaffected, but efficiently prevents binding of collagen to Glycoprotein VI and von Willebrand factor. Thus, LAIR-2/Fc has the
capacity to interfere with platelet-collagen interactions mediated by Glycoprotein VI and the VWF/Glycoprotein Ib axis.
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Introduction
The formation of platelet-rich thrombi is a multistep process
involving several components [1]. The initial step of thrombus
formation requires the capturing of platelets from flowing blood to
the exposed subendothelial matrix of an injured vessel wall. Once
bound to this matrix, platelets become activated, allowing the
formation of platelet-platelet interactions which is needed for
thrombus growth. Platelet activation is enhanced via thrombin, a
product of the coagulation cascade or via stimulatory agents (such
as ADP, epinephrine and thromboxane A2) that are released from
platelet storage granules. Finally, this primary activation and
aggregation step is followed by a second wave of signals that lead
to stabilization of the platelet aggregate [2].
The first step in the recruitment of platelets to the injured
v e s s e lw a l li sm e d i a t e db yt h ep l a t elet glycoprotein (Gp) Ib/IX/
V receptor complex, one of the most abundant receptors present
at the platelet surface. The main ligand for this GpIb/IX/V
complex is von Willebrand factor (VWF), a multimeric plasma
protein that functions as a molecular bridge between compo-
nents of the exposed subendothelial matrix (in particular
collagen) and the platelet GpIb/IX/V complex. The interaction
between VWF and GpIb/IX/V is of importance not only within
arterial and/or stenosed vessels, but also within venous vessels.
Indeed, studies using VWF-deficient mice have shown that the
absence of VWF is associated with delayed platelet adhesion and
defective thrombus formation in vessels with high and low shear
rates [3,4].
Interactions between platelets and subendothelial collagen
structures also occur in a direct manner. Two main collagen
receptors have been identified on platelets: the integrin a2b1 and a
member of the immunoglobulin superfamily, glycoprotein VI
(GpVI) [5]. Defining the respective roles of both receptors in the
platelet-collagen interaction is still a matter of debate [6]. At lower
shear rates, both receptors have the potential to contribute to the
adhesion of platelets to collagen. Under conditions of high blood
shear (.1500 s
21), the contribution of both receptors to initial
platelet adhesion is negligible and adhesion is fully dependent on
VWF. This does not mean, however, that both receptors are of
minor importance. Both GpVI and a2b1 have been shown to be
required for stable adhesion of platelets to a collagen surface. In
addition, both receptors are coupled to intracellular signaling
pathways that contribute to further platelet activation and
aggregation as well as the stabilization of platelet aggregates [6].
We identified the inhibitory immune receptor LAIR-1 as a high
affinity receptor for collagen [7,8]. In addition, its soluble family
member LAIR-2 is capable of binding collagen and is a potent
antagonist of the LAIR-1/collagen interaction [9]. Since multiple
binding sites for LAIR-1 and LAIR-2 are present on both human
collagens I and III [10], we hypothesized that soluble LAIR proteins
are capable of interfering with collagen-platelet interactions.
Surprisingly, we observed that LAIR-2 but not LAIR-1 efficiently
interferes with collagen-dependent platelet aggregation and adhesion.
Materials and Methods
Ethics statement
For donation of peripheral blood, all donors gave written
informed consent and approval was obtained from the Institu-
tional Review Board at University Medical Center Utrecht.
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Blood was collected from healthy volunteers, who did not use
aspirin in the preceding 10 days, in 1/10 volume of 0.13 M
sodium citrate and used for the preparation of platelet-rich plasma
(PRP). For FACS staining, PRP was supplemented with 0.1 vol
ACD (2.5% tri-sodium citrate, 1.5% citric acid and 2.0% D-
glucose). After washing with Hepes-Tyrode buffer (0.15 mM
NaCl, 5 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4,1 0m M
Hepes, pH 6.5) supplemented with prostaglandin I2 (10 ng/ml
final concentration), platelets were resuspended in Hepes-Tyrode
buffer (pH 7.4). CHO-cells expressing human a2b1 were a kind
gift from Dr. H. Deckmyn, University of Leuven, Belgium [11].
K562-cells transfected with LAIR-1 were described previously [7].
GpVI-expressing Jurkat-cells were prepared a follows: GpVI
cDNA (a kind gift of Dr M. Tomlinson, University of Birmingham)
was cloned into pMX retroviral vector. Retroviral-based con-
structs were packaged using the pCL-ampho system [7] and the
virus was used to infect Jurkat-cells. Three days after transduction,
transfectants expressing GPVI were sorted for high expression on
the cell surface using a flow cytometer (FACSAria; BD
Biosciences). For FACS analysis, antibodies recognizing the a2-
subunit of human a2b1 (CD49b, Clone AK-7, Biolegend), human
GpVI (a kind gift from Dr M. Kahn, University of Pennsylvania),
human LAIR-1 (Clone DX26, BD Biosciences) and CD62L (BD
Biosciences) were used. For Western blotting the following
antibodies were used: in-house mouse monoclonal antibody
against human LAIR-1 (clone 8A8), mouse monoclonal antibody
against human LAIR-2 (clone 3H12, kindly provided by Dr. B.
Jin, Fourth Military Medical University, Xi’an, China), and
polyclonal rabbit anti human GpVI (kindly provided by Dr. P.A.
Smethurst, University of Cambridge, UK). For inhibition studies
using Fc-fusion proteins, recombinant chimeric proteins of the
extracellular domain of hLAIR-1 or LAIR-2 fused to the Fc region
of human IgG1 (LAIR-1/Fc and LAIR-2/Fc, respectively) were
prepared as described previously [12]. A chimeric construct of the
Signal Inhibitory Receptor on Leukocytes-1 (SIRL-1) fused to the
Fc region of human IgG1 (SIRL-1/Fc) was used as control Fc
protein. SIRL-1 is an Ig-like receptor with one extracellular Ig-
domain and displays structural homology to LAIR-1 and LAIR-2
[13].
Platelet adherence under flow
Human placenta type III collagen (Sigma) was immobilized
onto ThermanoxH coverslips by a coating procedure resulting in a
concentration of 10 mg/cm
2. Coverslips were subsequently
blocked (16–20 h at 4uC) with 1% human albumin in phos-
phate-buffered saline (PBS). Perfusions were carried out using
citrated human whole blood in a triplicate single-passage parallel-
plate perfusion chamber as described [14] in the absence or
presence of LAIR-1/Fc, LAIR-2/Fc or control SIRL-1/Fc. Blood
was perfused over collagen-coated coverslips for 5 min at various
shear rates. After perfusion, slides were washed with Hepes buffer
(10 mM Hepes, 150 mM NaCl, pH 7.4) and fixed in 0.5%
glutaraldehyde in PBS. Slides were dehydrated in methanol and
stained with May-Gru ¨nwald and Giemsa. Platelet adhesion was
evaluated using computer-assisted analysis with OPTIMAS 6.0
software (Dutch Vision Systems (DVS), Breda, The Netherlands).
Platelet attachment to surface-bound collagen was expressed as
percentage surface coverage.
Platelet aggregation
Aggregation studies were carried out with PRP (2–2.56
10
5 platelets/ml) using an optical aggregometer (Chronolog,
Havertown PA, USA). Platelet poor plasma was used to set
baseline. Various concentrations of Horm collagen (Nycomed)
were pre-incubated with indicated amounts of Fc-fusion proteins
for 10 min at 37uC and incubated with PRP for 15 min at 37uC.
As control for collagen-independent aggregation, 50 mM thrombin
receptor activating peptide (TRAP) was added to PRP.
Collagen binding to LAIR-1, GpVI and a2b1
Collagen binding to transfectants was assessed by flow
cytometry as described previously [11]. In brief, collagen I was
labeled with FITC (Molecular Probes) in 0.05 M H3BO3, 0.2 M
NaCl (pH 9.2). After two hours, collagen was dialysed overnight
against 0.1 M Tris-HCl, 0.2 M NaCl (pH 7.4) to remove unbound
FITC. K562-cells stably transduced with LAIR-1 and Jurkat-cells
stably transduced with GPVI were incubated with FITC-labeled
collagen for 20 min. To activate a2b1 receptor, CHO-cells
expressing a2b1 were incubated in the presence of 1 mM MnCl2.
After 1 h at 37uC, cells were washed with PBS/10 mM NHCl4
and stained with FITC-labeled collagen. Cells were analyzed by
flow cytometry (LSRII, BD Biosciences).
VWF binding to collagen
Microtiter wells were coated with collagen I or collagen III
(50 mg/ml) in PBS (pH 7.4) for 16 h at 4uC. After washing three
times with PBS/0.01% Tween-20, wells were incubated with
purified plasma-derived VWF (0.1 mg/ml) in the absence or
presence of recombinant LAIR-1/Fc, LAIR-2/Fc or SIRL-1/Fc
(0-100 mg/ml for 1.5 h at 37uC. After washing three times with
PBS/0.01% Tween-20, bound VWF was determined via incuba-
tion with horseradish-conjugated polyclonal anti-human VWF
antibodies (DAKO, Denmark), 1:3000 diluted in PBS/0.01%
Tween-20 for 1.5 h at 37uC. After three washes with PBS/0.01%
Tween-20, bound antibodies detecting residual VWF were
visualized via incubation with 3-39-5-59-tetramethylbenzidine.
Results
Platelets do not express LAIR-1 or its soluble counterpart
LAIR-2
LAIR-1 and LAIR-2 are both collagen-binding proteins, which
are expressed by most haematopoietic cells [15]. Since binding of
platelets to the collagen-matrix is an important event in the
haemostatic process, we tested if platelets express LAIR-1 and/or
LAIR-2. Since we previously observed that unstimulated platelets
do not have surface expression of LAIR-1 ([16] and Steevels et al,
Manuscript submitted for publication), we now tested whether
upon activation platelets LAIR-1 expression was induced.
Whereas platelets stimulated with TRAP stained positive for
CD62L when analyzed by flow cytometry, no surface LAIR-1 was
detected (Fig. 1A). LAIR-1 surface expression was also undetect-
able on platelets stimulated by collagen or ADP (data not shown).
The presence of LAIR-1 or LAIR-2 in platelets was also assessed
using Western blotting of whole platelet lysates. Whereas the
presence of GpVI in lysates was readily detected, no LAIR-1 or
LAIR-2 protein could be detected (Fig. 1B). This let us to conclude
that platelets contain no detectable LAIR protein.
LAIR-2/Fc but not LAIR-1/Fc inhibits platelet aggregation
LAIR-molecules share binding sites on collagens with GpVI
[7,10,8]. We therefore considered the possibility that soluble
LAIR-variants (LAIR-2 and/or recombinant derivatives of LAIR-
1) may be used to interfere with platelet-collagen interactions. This
was first tested in collagen- and TRAP-induced platelet aggrega-
tion experiments. PRP was incubated in the absence or presence of
LAIR-1/Fc, LAIR-2/Fc or control protein SIRL-1/Fc (100 mg/
LAIR-2 Inhibits Platelets
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aggregation (Fig. 2A). Collagen-induced aggregation was also
unaffected in the presence of LAIR-1/Fc or control protein SIRL-
1/Fc (Fig. 2B). In contrast, the presence of LAIR-2/Fc resulted in
complete inhibition of platelet aggregation (Fig. 2B). We next
determined the minimal inhibiting dose of LAIR-2/Fc. Platelet
aggregation in response to collagen (1.0 mg/ml) was performed in
the absence or presence of various concentrations of LAIR-2/Fc
(0.01, 0.1 and 1.0 mg/ml). Whereas platelet aggregation was
unaffected in the presence of 0.01 mg/ml and 0.1 mg/ml LAIR-2/
Fc, a marked reduction in platelet aggregation of more than 50%
was observed in the presence of 1.0 mg/ml LAIR-2/Fc (Fig. 2C).
In addition, a concentration of 1.0 mg/ml LAIR-2/Fc was able to
interfere with platelet aggregation in response to 0.5 mg/ml and
1.0 mg/ml collagen, but not in the presence of 2.0 mg/ml and
4 mg/ml (Fig. 2D). Taken together, these data indicate that LAIR-
2/Fc but not LAIR-1/Fc is able to interfere with collagen-induced
platelet aggregation.
LAIR-2/Fc but not LAIR-1/Fc inhibits platelet adhesion to
collagen
In another series of experiments, we tested the potential of LAIR-
1/Fc and LAIR-2/Fc to interfere with the adhesion of platelets to
collagen surfaces under conditions of flow. Glass coverslips coated
withcollagentypeIII wereperfused with citrated wholeblood inthe
absence or presence of LAIR-1/Fc, LAIR-2/Fc or control protein
SIRL-1/Fc (100 mg/ml; Fig. 3A). Quantitative analysis revealed
that a surface coverage of 21.363.6% (mean6SD) was obtained in
the absence of these proteins when blood was perfused at low shear
rate (300 s
21; Fig. 3B). A similar surface coverage was found when
LAIR-1/Fc or SIRL-1/Fc were added (18.268.1% and
17.566.4%,respectively).Incontrast,surface coveragewasreduced
Figure 1. Platelets do not express LAIR-1 or LAIR-2. Panel A: Flowcytometric analysis of washed platelets (2610E5/ml), unstimulated or
stimulated for 5 min at RT with 10 mM TRAP or 5000 nM PMA. Upper panels represent staining for CD62L, lower panels represent LAIR-1 staining.
Panel B: Western blots containing whole platelet lysates and controls were incubated with antibodies against LAIR-1 (lanes 1–3), LAIR-2 (lanes 4–8)o r
GpVI (lane 9). Lane 1: purified LAIR-1/Fc; lane 2: purified LAIR-2/Fc; lane 3: whole platelet lysate; lane 4: purified LAIR-1/Fc; lane 5: purified LAIR-2/Fc;
lane 6: conditioned medium of non-transfected human 293T cells; lane 7: conditioned medium of human 293T cells secreting LAIR-2; lane 8: whole
platelet lysate; lane 9: whole platelet lysate.
doi:10.1371/journal.pone.0012174.g001
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high shear rate (1500 s
21), surface coverage increased to
50.762.1% when performed in the absence of the Fc-fusion
proteins (Fig. 3C). Again, addition of control protein SIRL-1/Fc
resulted in a similar coverage (47.062.8%). Surface coverage was
slightly but not significantly reduced in the presence of LAIR-1/Fc
(34.3611.2%; p=0.067), and strongly reduced to 7.069.9%
(p,0.005) in the presence of LAIR-2/Fc (Fig. 3C). The inhibitory
potential of LAIR-2/Fc was then assessed in more detail in
additional flow adhesion experiments. As depicted in Fig. 3D, half-
maximal inhibition was obtained at 18 mg/ml and 30 mg/ml LAIR-
2/Fc at 300 s
21 and 1500 s
21, respectively. Apparently, LAIR-2/
Fc not only efficiently interferes with collagen-induced platelet
aggregation, but also inhibits platelet-collagen interactions at both
low and high shear rates.
LAIR-2 interferes with GpVI and VWF but not a2b1
binding to collagen
Various receptors support the adhesion of platelets to collagen
surfaces, including GpVI, a2b1 as well as the VWF/GpIb axis. It
was of interest therefore to investigate which of these pathways are
inhibited by LAIR-2/Fc. First, cells expressing GpVI or a2b1
were incubated with FITC-labeled collagen (7.7 mg/ml) in the
absence or presence of LAIR-1/Fc, LAIR-2/Fc or control fusion
Figure 2. LAIR-2/Fc inhibits collagen but not TRAP-induced platelet aggregation. Aggregation of platelet rich plasma (PRP) in response to
collagen was measured using an optical aggregometer. Panel A: Platelet aggregation in response to 50 mM TRAP alone (PBS) or in the presence of
100 mg/ml LAIR-1/Fc, LAIR-2/Fc or SIRL-1/Fc. Panel B: Platelet aggregation in response to collagen (1 mg/ml) alone (PBS) or in the presence of 100 mg/
ml LAIR-1/F, LAIR-2/Fc or SIRL-1/Fc. Panel C: Platelet aggregation in response to collagen (1 mg/ml) alone (PBS) or in the presence of 0.01 mg/ml,
0.1 mg/ml or 1.0 mg/ml LAIR-2/Fc. Panel D: Platelet aggregation in response to 0.5 mg/ml, 1 mg/ml, 2 mg/ml or 4 mg/ml collagen in the presence of
1.0 mg/ml LAIR-2/Fc.
doi:10.1371/journal.pone.0012174.g002
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collagen in the absence of these proteins resulted in significant
binding to GpVI- or a2b1-expressing cells, as analyzed by flow
cytometry (Fig. 4A). Binding of collagen to Mn
2+-stimulated a2b1-
expressing CHO-cells was unaffected by each of the fusion
proteins tested, but was markedly reduced in the presence of the
a2b1-blocking antibody 15D7 (Fig. 4B). Binding of collagen to
GpVI-expressing cells was also unaffected by the presence of
Figure 3. LAIR-2/Fc inhibits adhesion of platelets to collagen under flow conditions. Panel A: Collagen type III-coated coverslips were
perfused with whole blood in the absence or presence of 100 mg/ml soluble LAIR-1/Fc, LAIR-2/Fc or SIRL-1/Fc. Representative pictures are shown.
Perfusion was performed at a shear rate of 300 s
21 (upper panels) or 1500 s
21 (lower panels). Percentages below figures indicate percentage surface-
coverage for each individual photo. Panels B & C: Quantitative representation of surface coverage of collagen type III-coated coverslips that were
perfused in the absence or presence of 100 mg/ml soluble LAIR-1/Fc, LAIR-2/Fc or SIRL-1/Fc at 300 s
21 (panel B) or 1500 s
21 (panel C). Data represent
mean6SD of three independent perfusions. Panel D: Dose dependent inhibition of surface platelet coverage in the presence of LAIR-2/Fc at shear
rates of 300 s
21 (open symbols) or 1500 s
21 (closed symbols). *: p,0.005.
doi:10.1371/journal.pone.0012174.g003
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inhibited in the presence of LAIR-2/Fc (Fig. 4C).
Binding of VWF to collagen was addressed in an immunosor-
bent assay. Wells were coated with collagen type I or III (5 mg/
well) and incubated with purified plasma-derived VWF (0.1 mg/
ml) in the absence or presence of various concentrations fusion
protein. Binding VWF to collagen I or III was similar in the
absence or presence of LAIR-1/Fc or SIRL-1/Fc. In contrast, a
dose-dependent inhibition of VWF to both types of collagen was
observed in the presence of LAIR-2/Fc. Half-maximal inhibition
was observed at 3 and 22 mg/ml LAIR-2/Fc for collagen type I
and III, respectively. Thus, LAIR-2/Fc has the capacity to
interfere with platelet-collagen interactions mediated by GpVI and
VWF/GpIb.
Discussion
Undesired exposure of vessel-wall components following disrup-
tion of the atherosclerotic plaque is often a prelude to coronary
arterial thrombotic complications. Interactions between platelet
collagen-receptors like GpVI, a2b1 or the GpIb/VWF complex
and subendothelial collagen structures are central to the formation
of platelet-rich thrombi that occlude the vasculature. In the present
manuscript, we describe the use of a soluble human collagen-
binding protein, i.e. LAIR-2 as a tool to interfere with platelet-
collagen interactions. LAIR-2 nor its homologue LAIR-1 could be
detected in platelets, either by FACS-analysis or Western blotting of
wholeplatelet-lysates(Fig.1).Thissuggeststhat incontrast toGpVI,
a2b1 and VWF,bothcollagen-bindingproteinsarenotexpressedto
a significant extent in platelets. This may seem surprising from the
notion that LAIR-1 and LAIR-2 are expressed in numerous cells of
hematopoietic origin, including CD34+ stem cells [17,18]. More-
over, we recently established that LAIR-1 is surface-expressed in
megakaryoblasts (T.A.M. Steevels, G.H.A. Westerlaken, M.R.
Tijssen, P.J. Coffer, P.J. Lenting, J.W.N. Akkerman & L. Meyaard,
manuscript under revision). LAIR-1 contains two ITIM-motifs, and
its absence from platelets is possibly necessary to avoid the influx of
conflicting (i.e. inhibitory versus activating) collagen-induced signals
via LAIR-1 and the GpVI/FcRc complex, respectively. Indeed, co-
expression of LAIR-1 and GpVI results in silencing of collagen-
induced signaling via GpVI [19].
When added to PRP, LAIR-2/Fc but not LAIR-1/Fc was able
to interfere with collagen-induced platelet aggregation (Fig. 2).
LAIR-2/Fc mediated inhibition was found to be dose-dependent
and specific, given that no inhibition was observed upon TRAP-
induced platelet aggregation (Fig. 2). A LAIR-2/Fc specific
inhibition of platelet-collagen interactions was also observed in in
vitro perfusion experiments. The addition of LAIR-2/Fc to
anticoagulated whole blood resulted in a dramatic decrease in
the deposition of platelets when perfused over a collagen surface,
both at low (300 s
21) and high (1500 s
21) shear rates (Fig. 3). Since
different receptors dominate the interactions between platelets and
collagen at low and high shear rates, our findings indicate that
LAIR-2/Fc is able to interfere with the action of more than one
collagen-receptor. Indeed, whereas LAIR-2/Fc was unable to
interfere with the interaction between collagen and a2b1, LAIR-
2/Fc but not LAIR-1/Fc inhibited binding of collagen to GpVI-
expressing cells as well as binding of VWF to collagen (Figs. 4 and
5). These data are in agreement with the perfusion data, in that
GpVI is important in the adhesion of platelets to collagen under
low shear rate conditions, whereas VWF is pertinent to the
adhesion of platelets to collagen under high shear rate conditions.
One unexpected observation in our study is the difference
between LAIR-1/Fc and LAIR-2/Fc in their ability to interfere
with collagen-platelet interactions. First, the primary structure of
both proteins is highly homologous (.80% amino acid identity
between LAIR-2 and the collagen-binding domain of LAIR-1)
[20]. Second, both proteins display efficient binding to collagens
Figure 4. LAIR-2/Fc interferes with GpVI but not a2b1 binding
to collagen. Jurkat-cells expressing GpVI or CHO-cells expressing a2b1
(Mn
2+ activated) were incubated with FITC-labeled collagen I (7.7 mg/
ml) in the absence or presence of 0.5 mg/ml LAIR-1/Fc, LAIR-2/Fc or
SIRL-1/Fc. Residual collagen binding was subsequently analyzed via
FACS-analysis. Panel A: representative histograms for binding of FITC-
labeled collagen I to GpVI- or a2b1-expressing cells in the absence
(closed histograms) or presence (open histograms) of LAIR-2/Fc. Panel B:
Quantitative analysis of residual FITC-labeled collagen I binding to
a2b1-expressing cells in the absence or presence of Fc-fusion proteins
or the blocking a2b1 antibody MAb-15D7. Panel C: Quantitative analysis
of residual FITC-labeled collagen I binding to GpVI-expressing cells in
the absence or presence of Fc-fusion proteins. Data represent the
relative mean fluorescent intensity (expressed as % of PBS control) 6
SD of three independent experiments. *p,0.005 compared to control.
doi:10.1371/journal.pone.0012174.g004
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LAIR-2 (as determined using the collagen tool-kits) overlap to a
significant extent and collagen-binding is in both cases more
efficient when the sequences are enriched in Glycine-Proline-
Hydroxyproline (GPO)-triplets [10]. However, one important
difference which was revealed by determining the collagen
sequences that are being recognized by LAIR-1 and LAIR-2, is
that LAIR-2 not only recognizes similar sequences as LAIR-1, but
also a set of additional collagen-related motifs. This may explain
why LAIR-2 and LAIR-1 behave differently with regard to
platelet-collagen interactions.
The collagen toolkits have also been used to identify collagen
sequences that are being recognized by a2b1, GpVI and VWF
[21,22,23]. Both a2b1 and VWF recognize a single specific
collagen sequence (GFOGER/N and RGQOGVMGF, respec-
tively, with O being hydroxyproline), whereas GpVI seems to
interact efficiently with sequences that contain multiple GPO-
triplets. Since a similar preference for GPO-containing sequences
has also been found for LAIR-2, this may provide a rationale for
the inhibitory effect of LAIR-2/Fc on GpVI-collagen interactions.
However, this does not explain why LAIR-2/Fc is able to interfere
with VWF-collagen interactions, since the sequence recognized by
VWF is not recognized by LAIR-2. Approximately 10 LAIR-2/Fc
molecules bind per collagen monomer, whereas this amount is
limited to one for VWF. The possibility exists that the high
number of LAIR-2/Fc molecules (with a molecular weight of
82.5 kDa) prevent VWF from binding to collagen via steric
hindrance.
In view of the efficient inhibition of collagen-dependent platelet
adhesion and aggregation, it is of interest to speculate on the
(patho)physiological consequences of our findings. Considering the
low molecular weight of the genuine LAIR-2 protein (15–18 kDa)
the protein is likely to have a very short half-life in the circulation.
Indeed, using a sensitive antigen assay, LAIR-2 could not be
detected in plasma of healthy individuals [9]. Thus, it seems
inconceivable that LAIR-2 plays a relevant role in the regulation
of platelet-collagen conditions under normal haemostatic condi-
tions. However, LAIR-2 is mainly secreted by CD4
+ T cells,
suggesting that levels of LAIR-2 are locally increased at sites of
inflammation. This is illustrated by increased levels of LAIR-2 in
synovial fluid of patients with rheumatoid arthritis [24]. Interest-
ingly, it has recently been reported that platelet-derived micro-
particles contribute to the pathogenesis of inflammatory arthritis in
a GpVI-dependent manner [25]. It is tempting to speculate that
LAIR-2 secreted by locally active CD4
+ T cells could modulate
GpVI-mediated disease progression.
Given the efficient manner in which LAIR-2 interferes with
platelet-collagen interactions, also its therapeutical application as
inhibitor of collagen-dependent thrombosis should be considered.
In contrast to some of the collagen-inhibitors that are currently
being developed, such as Saratin and Aegyptin, the risk of the
formation of allo-antibodies is probably low in view of the human
origin of the LAIR-2 protein.
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